UC San Diego and GSK Collaborate to Eradicate Cancer Stem Cells, Treat Leukemia

First California institution selected to participate in GSK’s bench-to-bedside academia-industry collaboration program —

Researchers at the University of California, San Diego School of Medicine and Moores Cancer Center are working with GSK on a bench-to-bedside project to treat leukemia and other diseases by eliminating cancer stem cells. The collaboration is part of GSK’s Discovery Partnerships with Academia (DPAc) program, where academic partners become core members of drug-hunting teams. Catriona Jamieson, MD, PhD, associate professor of medicine and chief of the Division of Regenerative Medicine, will lead UC San Diego’s effort in the new DPAc team. … Read the full story from the UC San Diego Newsroom

Drug Targets Hard-to-Reach Leukemia Stem Cells Responsible for Relapses

Researchers at the University of California, San Diego School of Medicine have discovered that hard-to-reach, drug-resistant leukemia stem cells (LSCs) that overexpress multiple pro-survival protein forms are sensitive – and thus vulnerable – to a novel cancer stem cell-targeting drug currently under development. … Read the full story from the UCSD Newsroom


Catriona H. M. Jamieson, MD, PhDPrincipal investigator of the study is Catriona H. M. Jamieson, MD, PhD, associate professor of medicine in the Division of Hematology-Oncology and director of stem cell research at the UC San Diego Moores Cancer Center.

Dr. Jamieson is on the steering committee for the Moores Cancer Center’s My Answer to Cancer initiative for personalized cancer therapy. She is a member of the faculty in the UCSD Biomedical Sciences Graduate Program.

Citation for the report: Goff DJ, Recart AC, Sadarangani A, Chun H-J, Barrett CL, Krajewska M, Leu H, Low-Marchelli J, Ma W, Shih AY, Wei J, Zhai D, Geron I, Pu M, Bao L, Chuang R, Balaian L, Gotlib J, Minden M, Martinelli G, Rusert J, Dao K-H, Shazand K, Wentworth P, Smith KM, Jamieson CAM, Morris SR, Messer K, S.B. Goldstein LSB, Hudson TJ, Marra M, Frazer KA, Pellecchia M, Reed JC, and Jamieson CHM. (2013) A Pan-BCL2 Inhibitor Renders Bone-Marrow-Resident Human Leukemia Stem Cells Sensitive to Tyrosine Kinase Inhibition. Cell Stem Cell 10.1016/j.stem.2012.12.011, online January 17, 2013.

More about Dr. Jamieson and her work:

Enzyme Accelerates Malignant Stem Cell Cloning in Chronic Myeloid Leukemia

An international team, headed by researchers at the University of California, San Diego School of Medicine, has identified a key enzyme in the reprogramming process that promotes malignant stem cell cloning and the growth of chronic myeloid leukemia (CML), a cancer of the blood and marrow that experts say is increasing in prevalence. … Read the full story from the UCSD Newsroom


Catriona H. M. Jamieson, MD, PhDPrincipal investigator of the study is Catriona H. M. Jamieson, MD, PhD, associate professor of medicine in the Division of Hematology-Oncology and director of stem cell research at the UC San Diego Moores Cancer Center.

Dr. Jamieson is on the steering committee for the Moores Cancer Center’s My Answer to Cancer initiative for personalized cancer therapy. She is a member of the faculty in the UCSD Biomedical Sciences Graduate Program.

Department of Medicine faculty coauthor Sheldon R. Morris, MD, MPH, an investigator at the UCSD Antiviral Research Center,is health sciences assistant clinical professor in the Division of Infectious Diseases.

Citation for the report in PNAS: Jiang Q, Crews LA, Barrett CL, Chun H-J, Court AC, Isquith JM, Zipeto MA, Goff DJ, Minden M, Sadarangani A, Rusert JM, Dao K-HT, Morris SR, Goldstein LSB, Marra MA, Kelly A. Frazer KA, Jamieson C.H.M. ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia. PNAS 2012; published ahead of print December 28, 2012, doi:10.1073/pnas.1213021110

Read the study report (free full text)

More about Dr. Jamieson and her work: